Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaHagop Kantarjian, Brian Druker|New England Journal of Medicine|2002Cited by 2k
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaHagop Kantarjian, Emil J. Freireich, Farhad Ravandi et al.|Blood|2010Cited by 399
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsJörge E. Cortes, Dan Jones, Francis J. Giles et al.|Blood|2007Cited by 298
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Hagop Kantarjian, Peter F. Thall et al.|Haematologica|2015Cited by 121
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Hagop Kantarjian, Nicola Gökbuget et al.|Leukemia Research|2019Cited by 52